Current Report Filing (8-k)
June 25 2018 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
June 19, 2018
ENOCHIAN BIOSCIENCES INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-54478
|
|
45-2559340
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
Century City Medical Plaza
2080 Century City East
Suite 906
Los Angeles, CA 90067
(Address of principal executive offices)
|
+1(510) 203-4857
(Registrant’s telephone number,
including area code)
Stumpedyssevej
17,
2970
Horsholm, Denmark
(Former address, if changed since last
report.)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01
Entry into a Material Definitive Agreement.
On
June 19, 2018, Enochian Biosciences, Inc., a Delaware corporation (the “Company”), entered into a Lease Agreement (the
“Lease Agreement”) for a term of ten years from September 1, 2018 (the “Term”) with Century City Medical
Plaza Land Co., Inc., a California Corporation, as landlord (the “Landlord”), pursuant to which the Company agreed
to lease from the Landlord certain premises (the “Leased Premises”) located in Los Angeles.
The
Leased Premises consist of 2,453 rentable square feet. The base rent for the Leased Premises increases by 3% each year over the
Term, and ranges from $12,265.00 per month for the first year to $16,003.04 per month for the tenth year. The Company is entitled
to $108,168.00 in contributions toward tenant improvements.
The
Loan is a long-term debt obligation as defined in Item 303(a)(5)(ii)(A) of Regulation S-K that is material to the Company.
The
foregoing description of the Lease Agreement does not purport to be complete. For a complete description of all the terms of the
Lease Agreement, please refer to the full text of the Lease Agreement, a copy of which is filed herewith as Exhibit 10.1, to this
Current Report on Form 8-K and incorporated into this Item 1.01 by reference.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information
under Item 1.01 above is incorporated by reference into this Item 2.03, and is qualified in its entirety by reference to the full
text of the Lease Agreement, a copy of which is filed herewith as Exhibit 10.1, to this Current Report on Form 8-K and incorporated
into this Item 2.03 by reference.
Item 9.01 Financial Statements
and Exhibits
.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ENOCHIAN BIOSCIENCES, INC.
|
|
|
|
By:
|
/s/ Eric Leire
|
|
|
Name: Eric Leire
Title: Chief Executive Officer
|
Date: June 25, 2018
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Sep 2023 to Sep 2024